HHLR Advisors’s Axsome Therapeutics AXSM Stock Holding History

HHLR Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100,000	Closed	-$6.99M	–	52
2023 Q3	$6.99M	Hold	100,000	–	–	0.16%	41
2023 Q2	$7.19M	Buy	+100,000	New	+$7.38M	0.15%	39
2021 Q3	–	Sell	-360,000	Closed	-$24.3M	–	88
2021 Q2	$24.3M	Hold	360,000	–	–	0.25%	49
2021 Q1	$20.4M	Hold	360,000	–	–	0.2%	47
2020 Q4	$29.3M	Buy	+360,000	New	+$26.9M	0.23%	50

Other funds holding AXSM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

HHLR Advisors's AXSM Position: Q4 2023 in Review

HHLR Advisors sold out of Axsome Therapeutics (AXSM) in Q4 2023, closing a stake of 100,000 shares — an estimated $6.99M sold.

HHLR Advisors first reported a position in AXSM in Q4 2020 and held it in 5 quarters. The position peaked at $29.3M in Q4 2020. 244 funds tracked by Wall St. Rank hold AXSM as of Q4 2023.

HHLR Advisors reported no remaining Axsome Therapeutics position as of Q4 2023 after selling out during the quarter.
HHLR Advisors sold 100,000 Axsome Therapeutics shares in Q4 2023, an estimated $6.99M.
HHLR Advisors first reported a position in Axsome Therapeutics in Q4 2020 and held it in 5 quarters.
HHLR Advisors's Axsome Therapeutics position peaked at $29.3M in Q4 2020.
244 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2023.

Based on HHLR Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.